Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
34.64
-0.07 (-0.20%)
Aug 31, 2026, 4:00 PM EDT - Market closed
Roivant Sciences Revenue
Roivant Sciences had revenue of $1.44M in the quarter ending June 30, 2026, a decrease of -33.55%. This brings the company's revenue in the last twelve months to $7.53M, down -67.58% year-over-year. In the fiscal year ending March 31, 2026, Roivant Sciences had annual revenue of $8.26M, down -71.57%.
Revenue (ttm)
$7.53M
Revenue Growth
-67.58%
P/S Ratio
3,322.00
Revenue / Employee
$10,447
Employees
721
Market Cap
25.02B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 8.26M | -20.79M | -71.57% |
| Mar 31, 2025 | 29.05M | -3.66M | -11.19% |
| Mar 31, 2024 | 32.71M | -28.57M | -46.62% |
| Mar 31, 2023 | 61.28M | 5.99M | 10.84% |
| Mar 31, 2022 | 55.29M | 31.49M | 132.34% |
| Mar 31, 2021 | 23.80M | -43.89M | -64.85% |
| Mar 31, 2020 | 67.69M | 65.37M | 2,812.61% |
| Mar 31, 2019 | 2.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| Alnylam Pharmaceuticals | 4.80B |
| Jazz Pharmaceuticals | 4.60B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
| Ascendis Pharma | 1.20B |
ROIV News
- 3 days ago - Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month - Reuters
- 3 days ago - Roivant Sciences Transcript: FDA announcement - Transcripts
- 3 days ago - Roivant Sciences Press release: FDA announcement - Filings
- 3 days ago - Roivant Sciences Slides: FDA announcement - Filings
- 4 days ago - US FDA approves Roivant-Priovant's skin and muscle disease drug - Reuters
- 4 days ago - Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. - GlobeNewsWire
- 4 days ago - Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. - GlobeNewsWire
- 5 days ago - JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis - GlobeNewsWire